| Market Capitalization (Millions $) |
32,923 |
| Shares
Outstanding (Millions) |
153 |
| Employees |
1,280 |
| Revenues (TTM) (Millions $) |
4,493 |
| Net Income (TTM) (Millions $) |
825 |
| Cash Flow (TTM) (Millions $) |
155 |
| Capital Exp. (TTM) (Millions $) |
164 |
Business Description
Illumina Inc. is a prominent American biotechnology company that specializes in developing and manufacturing tools for genetic analysis. Founded in 1998 and headquartered in San Diego, California, Illumina has established itself as a leader in the field of genomics, particularly known for its advancements in next-generation sequencing (NGS) technologies.
Key Products and Technologies
Illuminas flagship product line includes the Genome Analyzer, an NGS platform that allows for high-throughput DNA sequencing. The company’s sequencing systems leverage proprietary chemistry and advanced software algorithms to deliver highly accurate and reliable genomic data. This capability enables researchers to investigate genetic variations and unravel complex disease pathways.
In addition to the Genome Analyzer, Illumina offers a variety of other products, including:
- Microarrays: Tools used for genotyping and gene expression profiling.
- PCR (Polymerase Chain Reaction) kits: Essential for amplifying DNA sequences in various applications.
- Software platforms: Integrated solutions for managing data generated from sequencing and analysis, facilitating better visualization and interpretation of genomic data.
Applications and Impact
Illuminas products find applications across multiple sectors, including:
- Healthcare: Enhancing diagnostics and personalized medicine by enabling genomic profiling and cancer genomics.
- Research: Providing essential tools for academic and clinical research, thereby advancing our understanding of genetic disorders and diseases.
- Agriculture: Supporting genomic studies that improve crop quality and yield through genetic analysis.
The company collaborates with pharmaceutical and biotechnology firms, as well as academic institutions, to pioneer new therapies and treatments for challenging health issues such as cancer, diabetes, and rare genetic diseases.
Services
Illumina also provides comprehensive sequencing and data analysis services, catering to both research applications and clinical diagnostics. This includes supporting initiatives like population genomics and large-scale health studies, which aim to uncover actionable insights from genomic data.
Commitment to Innovation
Illumina maintains a strong dedication to innovation, investing significantly in research and development to advance its technology offerings. The company has introduced numerous enhancements to its sequencing platforms, striving to lower costs and increase throughput while improving data quality.
Noteworthy Initiatives
The company has been involved in several major scientific and genomic initiatives, such as:
- The 100,000 Genomes Project in the UK, aimed at understanding rare diseases and cancer through extensive genomic sequencing.
- The All of Us Research Program in the United States, which seeks to gather health data from diverse populations to promote personalized medicine and enhance health outcomes.
Conclusion
Illumina Inc. is a cornerstone of the genomic analysis landscape, providing sophisticated technology and solutions that empower researchers and healthcare professionals. Through its continuous innovation and strategic partnerships, Illumina plays a pivotal role in advancing scientific knowledge and improving healthcare outcomes worldwide.
Company Address: 5200 Illumina Way San Diego 92122 CA
Company Phone Number: 202-4500 Stock Exchange / Ticker: NASDAQ ILMN
|
5.66% 
163.85 %